Ryan Cole explores CAR-T therapy, where patients' immune cells are genetically reprogrammed to hunt cancer. With FDA-approved treatments achieving 83% remission rates in previously untreatable blood cancers, this breakthrough demonstrates medicine's shift toward programmable cell therapy. Cole examines engineering challenges, logic gates, and biology's transformation into executable code.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
Show More
Show Less